Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-05-20

AUTHORS

Andreas Teufel, Michael Gerken, Janine Hartl, Timo Itzel, Stefan Fichtner-Feigl, Christian Stroszczynski, Hans Jürgen Schlitt, Ferdinand Hofstädter, Monika Klinkhammer-Schalke

ABSTRACT

BACKGROUND: Colorectal cancer is the third most common cancer and a major cause of morbidity and mortality worldwide. Adjuvant chemotherapy is considered the standard of care in patients with UICC stage III colon cancer after R0 resection. Adjuvant therapy was not shown to be beneficial in patients with UICC stage II colon cancer. However, there is an ongoing discussion as to whether adjuvant chemotherapy may be beneficial for a subgroup of UICC II patients in a "high-risk situation" (such as T4). METHODS: We investigated a Bavarian population-based (2.1 million inhabitants) cohort of 1937 patients with UICC II CRC treated between 2002 and 2012 in regard of the benefit of adjuvant chemotherapy for large (T4) tumors. Patients older than 80 years of age were excluded. Of 1937 patients, 240 had a T4 tumor (12%); 77 of all T4 patients received postoperative chemotherapy (33%). Kaplan-Meier analysis and Cox regression models were used for survival analyses. RESULTS: Patients with a T4 tumor who received postoperative chemotherapy had a highly significant survival benefit in respect of overall survival (p<0.001) and recurrence-free survival (p=0.008). However, no difference was observed between oxaliplatin-containing and non-oxaliplatin-containing treatment regimens. G2 and G3 tumors were found to particularly benefit from adjuvant treatment. Chemotherapy, age at diagnosis, and tumor grading remained independent risk factors in the multivariate cox regression analysis. CONCLUSION: Our retrospective study demonstrated the significant benefit of adjuvant chemotherapy in the T4 subgroup of patients with UICC II colon cancer. Our data suggest that adjuvant chemotherapy should be seriously considered in these patients. More... »

PAGES

419

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-015-1404-9

DOI

http://dx.doi.org/10.1186/s12885-015-1404-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010206679

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25985893


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colonic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Grading", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxaliplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine I, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Medicine I, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teufel", 
        "givenName": "Andreas", 
        "id": "sg:person.0705653251.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705653251.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tumor Center, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Tumor Center, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gerken", 
        "givenName": "Michael", 
        "id": "sg:person.013647415541.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647415541.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine I, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Medicine I, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hartl", 
        "givenName": "Janine", 
        "id": "sg:person.0637310151.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637310151.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine I, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Medicine I, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Itzel", 
        "givenName": "Timo", 
        "id": "sg:person.01114704666.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114704666.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Surgery, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fichtner-Feigl", 
        "givenName": "Stefan", 
        "id": "sg:person.01171747331.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171747331.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Radiology, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stroszczynski", 
        "givenName": "Christian", 
        "id": "sg:person.01304333475.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304333475.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Department of Surgery, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schlitt", 
        "givenName": "Hans J\u00fcrgen", 
        "id": "sg:person.010361144542.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tumor Center, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Tumor Center, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofst\u00e4dter", 
        "givenName": "Ferdinand", 
        "id": "sg:person.01052221134.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052221134.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tumor Center, University of Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7727.5", 
          "name": [
            "Tumor Center, University of Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klinkhammer-Schalke", 
        "givenName": "Monika", 
        "id": "sg:person.01055256602.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055256602.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015-05-20", 
    "datePublishedReg": "2015-05-20", 
    "description": "BACKGROUND: Colorectal cancer is the third most common cancer and a major cause of morbidity and mortality worldwide. Adjuvant chemotherapy is considered the standard of care in patients with UICC stage III colon cancer after R0 resection. Adjuvant therapy was not shown to be beneficial in patients with UICC stage II colon cancer. However, there is an ongoing discussion as to whether adjuvant chemotherapy may be beneficial for a subgroup of UICC II patients in a \"high-risk situation\" (such as T4).\nMETHODS: We investigated a Bavarian population-based (2.1 million inhabitants) cohort of 1937 patients with UICC II CRC treated between 2002 and 2012 in regard of the benefit of adjuvant chemotherapy for large (T4) tumors. Patients older than 80 years of age were excluded. Of 1937 patients, 240 had a T4 tumor (12%); 77 of all T4 patients received postoperative chemotherapy (33%). Kaplan-Meier analysis and Cox regression models were used for survival analyses.\nRESULTS: Patients with a T4 tumor who received postoperative chemotherapy had a highly significant survival benefit in respect of overall survival (p<0.001) and recurrence-free survival (p=0.008). However, no difference was observed between oxaliplatin-containing and non-oxaliplatin-containing treatment regimens. G2 and G3 tumors were found to particularly benefit from adjuvant treatment. Chemotherapy, age at diagnosis, and tumor grading remained independent risk factors in the multivariate cox regression analysis.\nCONCLUSION: Our retrospective study demonstrated the significant benefit of adjuvant chemotherapy in the T4 subgroup of patients with UICC II colon cancer. Our data suggest that adjuvant chemotherapy should be seriously considered in these patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-015-1404-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "adjuvant chemotherapy", 
      "colon cancer", 
      "postoperative chemotherapy", 
      "T4 tumors", 
      "UICC stage III colon cancer", 
      "stage III colon cancer", 
      "multivariate Cox regression analysis", 
      "stage II colon cancer", 
      "significant survival benefit", 
      "independent risk factor", 
      "recurrence-free survival", 
      "Cox regression analysis", 
      "population-based cohort", 
      "Kaplan-Meier analysis", 
      "Cox regression model", 
      "standard of care", 
      "years of age", 
      "T4 patients", 
      "T4 subgroups", 
      "R0 resection", 
      "adjuvant therapy", 
      "adjuvant treatment", 
      "survival benefit", 
      "overall survival", 
      "II patients", 
      "retrospective study", 
      "colorectal cancer", 
      "treatment regimens", 
      "G3 tumors", 
      "common cancer", 
      "large tumors", 
      "risk factors", 
      "tumor grading", 
      "chemotherapy", 
      "patients", 
      "high-risk situations", 
      "survival analysis", 
      "cancer", 
      "tumors", 
      "major cause", 
      "regression analysis", 
      "regression models", 
      "survival", 
      "age", 
      "significant benefits", 
      "subgroups", 
      "morbidity", 
      "resection", 
      "regimens", 
      "therapy", 
      "cohort", 
      "mortality", 
      "diagnosis", 
      "benefits", 
      "care", 
      "CRC", 
      "treatment", 
      "grading", 
      "cause", 
      "years", 
      "G2", 
      "factors", 
      "differences", 
      "analysis", 
      "study", 
      "ongoing discussion", 
      "regard", 
      "data", 
      "standards", 
      "situation", 
      "discussion", 
      "model", 
      "respect", 
      "III colon cancer", 
      "UICC stage II colon cancer", 
      "II colon cancer", 
      "UICC II patients", 
      "Bavarian population-based (2.1 million inhabitants) cohort", 
      "UICC II CRC", 
      "II CRC", 
      "UICC II colon cancer", 
      "T4 UICC II colon cancer"
    ], 
    "name": "Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer", 
    "pagination": "419", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010206679"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-015-1404-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25985893"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-015-1404-9", 
      "https://app.dimensions.ai/details/publication/pub.1010206679"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_652.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-015-1404-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1404-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1404-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1404-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1404-9'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      21 PREDICATES      124 URIs      116 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-015-1404-9 schema:about N094d8e2940024e4b93306a971b179033
2 N1bbe566651544c50803933a454d8ef82
3 N3d34e42147154402b5c94eb856d6b12b
4 N415a65d13ce2417d997c101855adf7cd
5 N697b273ef8e74d9aad1a3911fb925db7
6 N7fda1638a9af477f913fce109b5fde7c
7 N8f8a9a6b00a247d2acab6f81a8d99e97
8 N98ec8fe826e9432eab1d5f9abeeb5cfe
9 Na2eddf90ffd549e392433e7c8c8db9ae
10 Nbca861a6220e4888b19631cbba69ef14
11 Nca4e94167455406c84e14863b5b6d2a8
12 Ncdb7018b5a494018a79755fc77863a76
13 Ndd7b0eed8aaf49e4a452a295a392f25f
14 Ne0bf2ae1a73d4ef3b93b6316897a111a
15 Ne213f3a9a8a64ee39a3fe495f184e46d
16 Nff37b685300b44f5bc8f987edf064328
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Na07d98126d48444aa58bfb6e8a135ad4
20 schema:datePublished 2015-05-20
21 schema:datePublishedReg 2015-05-20
22 schema:description BACKGROUND: Colorectal cancer is the third most common cancer and a major cause of morbidity and mortality worldwide. Adjuvant chemotherapy is considered the standard of care in patients with UICC stage III colon cancer after R0 resection. Adjuvant therapy was not shown to be beneficial in patients with UICC stage II colon cancer. However, there is an ongoing discussion as to whether adjuvant chemotherapy may be beneficial for a subgroup of UICC II patients in a "high-risk situation" (such as T4). METHODS: We investigated a Bavarian population-based (2.1 million inhabitants) cohort of 1937 patients with UICC II CRC treated between 2002 and 2012 in regard of the benefit of adjuvant chemotherapy for large (T4) tumors. Patients older than 80 years of age were excluded. Of 1937 patients, 240 had a T4 tumor (12%); 77 of all T4 patients received postoperative chemotherapy (33%). Kaplan-Meier analysis and Cox regression models were used for survival analyses. RESULTS: Patients with a T4 tumor who received postoperative chemotherapy had a highly significant survival benefit in respect of overall survival (p<0.001) and recurrence-free survival (p=0.008). However, no difference was observed between oxaliplatin-containing and non-oxaliplatin-containing treatment regimens. G2 and G3 tumors were found to particularly benefit from adjuvant treatment. Chemotherapy, age at diagnosis, and tumor grading remained independent risk factors in the multivariate cox regression analysis. CONCLUSION: Our retrospective study demonstrated the significant benefit of adjuvant chemotherapy in the T4 subgroup of patients with UICC II colon cancer. Our data suggest that adjuvant chemotherapy should be seriously considered in these patients.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf Na1f046338c1042f698ff4ca23fd6f243
27 Naae1fb3f19b64eacb8e6fe5564e37e5f
28 sg:journal.1024632
29 schema:keywords Bavarian population-based (2.1 million inhabitants) cohort
30 CRC
31 Cox regression analysis
32 Cox regression model
33 G2
34 G3 tumors
35 II CRC
36 II colon cancer
37 II patients
38 III colon cancer
39 Kaplan-Meier analysis
40 R0 resection
41 T4 UICC II colon cancer
42 T4 patients
43 T4 subgroups
44 T4 tumors
45 UICC II CRC
46 UICC II colon cancer
47 UICC II patients
48 UICC stage II colon cancer
49 UICC stage III colon cancer
50 adjuvant chemotherapy
51 adjuvant therapy
52 adjuvant treatment
53 age
54 analysis
55 benefits
56 cancer
57 care
58 cause
59 chemotherapy
60 cohort
61 colon cancer
62 colorectal cancer
63 common cancer
64 data
65 diagnosis
66 differences
67 discussion
68 factors
69 grading
70 high-risk situations
71 independent risk factor
72 large tumors
73 major cause
74 model
75 morbidity
76 mortality
77 multivariate Cox regression analysis
78 ongoing discussion
79 overall survival
80 patients
81 population-based cohort
82 postoperative chemotherapy
83 recurrence-free survival
84 regard
85 regimens
86 regression analysis
87 regression models
88 resection
89 respect
90 retrospective study
91 risk factors
92 significant benefits
93 significant survival benefit
94 situation
95 stage II colon cancer
96 stage III colon cancer
97 standard of care
98 standards
99 study
100 subgroups
101 survival
102 survival analysis
103 survival benefit
104 therapy
105 treatment
106 treatment regimens
107 tumor grading
108 tumors
109 years
110 years of age
111 schema:name Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
112 schema:pagination 419
113 schema:productId N68df2503be3a4c0cb76070d394c80f69
114 N6e45770fd93e468792a101d4a7c92403
115 Nac0b4d6c4e2246c88db6aeed3bd9240d
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010206679
117 https://doi.org/10.1186/s12885-015-1404-9
118 schema:sdDatePublished 2021-12-01T19:33
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N73e9d2112bfa4bb89b8874d58e531fd2
121 schema:url https://doi.org/10.1186/s12885-015-1404-9
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N094d8e2940024e4b93306a971b179033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged
127 rdf:type schema:DefinedTerm
128 N1bbe566651544c50803933a454d8ef82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Humans
130 rdf:type schema:DefinedTerm
131 N217c2e7f48504f33904690aa1b3db696 rdf:first sg:person.0637310151.42
132 rdf:rest N32d0571acda74881b5f81bd17aaf7251
133 N2435d07631e34f87b12748dd78aa7ae2 rdf:first sg:person.010361144542.53
134 rdf:rest Na2d18dca197f4628ae64878194d481a1
135 N32d0571acda74881b5f81bd17aaf7251 rdf:first sg:person.01114704666.73
136 rdf:rest N74693dc650884fe48c01044c2cb4f7d0
137 N3d34e42147154402b5c94eb856d6b12b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Neoplasm Staging
139 rdf:type schema:DefinedTerm
140 N415a65d13ce2417d997c101855adf7cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Disease-Free Survival
142 rdf:type schema:DefinedTerm
143 N4679b03f131f41e3987f3ce55ba0ebfd rdf:first sg:person.01055256602.17
144 rdf:rest rdf:nil
145 N68df2503be3a4c0cb76070d394c80f69 schema:name pubmed_id
146 schema:value 25985893
147 rdf:type schema:PropertyValue
148 N697b273ef8e74d9aad1a3911fb925db7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Chemotherapy, Adjuvant
150 rdf:type schema:DefinedTerm
151 N6e45770fd93e468792a101d4a7c92403 schema:name doi
152 schema:value 10.1186/s12885-015-1404-9
153 rdf:type schema:PropertyValue
154 N73e9d2112bfa4bb89b8874d58e531fd2 schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N74693dc650884fe48c01044c2cb4f7d0 rdf:first sg:person.01171747331.28
157 rdf:rest Nc1d11f6bb49449cb8bb91312ce700aa8
158 N7fda1638a9af477f913fce109b5fde7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Middle Aged
160 rdf:type schema:DefinedTerm
161 N8f8a9a6b00a247d2acab6f81a8d99e97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Neoplasm Grading
163 rdf:type schema:DefinedTerm
164 N96f8bd67f3234dec89820796aafa138e rdf:first sg:person.013647415541.23
165 rdf:rest N217c2e7f48504f33904690aa1b3db696
166 N98ec8fe826e9432eab1d5f9abeeb5cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Organoplatinum Compounds
168 rdf:type schema:DefinedTerm
169 Na07d98126d48444aa58bfb6e8a135ad4 rdf:first sg:person.0705653251.86
170 rdf:rest N96f8bd67f3234dec89820796aafa138e
171 Na1f046338c1042f698ff4ca23fd6f243 schema:volumeNumber 15
172 rdf:type schema:PublicationVolume
173 Na2d18dca197f4628ae64878194d481a1 rdf:first sg:person.01052221134.13
174 rdf:rest N4679b03f131f41e3987f3ce55ba0ebfd
175 Na2eddf90ffd549e392433e7c8c8db9ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Adenocarcinoma
177 rdf:type schema:DefinedTerm
178 Naae1fb3f19b64eacb8e6fe5564e37e5f schema:issueNumber 1
179 rdf:type schema:PublicationIssue
180 Nac0b4d6c4e2246c88db6aeed3bd9240d schema:name dimensions_id
181 schema:value pub.1010206679
182 rdf:type schema:PropertyValue
183 Nbca861a6220e4888b19631cbba69ef14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Oxaliplatin
185 rdf:type schema:DefinedTerm
186 Nc1d11f6bb49449cb8bb91312ce700aa8 rdf:first sg:person.01304333475.28
187 rdf:rest N2435d07631e34f87b12748dd78aa7ae2
188 Nca4e94167455406c84e14863b5b6d2a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Colonic Neoplasms
190 rdf:type schema:DefinedTerm
191 Ncdb7018b5a494018a79755fc77863a76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Age Factors
193 rdf:type schema:DefinedTerm
194 Ndd7b0eed8aaf49e4a452a295a392f25f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Survival Rate
196 rdf:type schema:DefinedTerm
197 Ne0bf2ae1a73d4ef3b93b6316897a111a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Fluorouracil
199 rdf:type schema:DefinedTerm
200 Ne213f3a9a8a64ee39a3fe495f184e46d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Retrospective Studies
202 rdf:type schema:DefinedTerm
203 Nff37b685300b44f5bc8f987edf064328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Antineoplastic Combined Chemotherapy Protocols
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
210 schema:name Oncology and Carcinogenesis
211 rdf:type schema:DefinedTerm
212 sg:journal.1024632 schema:issn 1471-2407
213 schema:name BMC Cancer
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.010361144542.53 schema:affiliation grid-institutes:grid.7727.5
217 schema:familyName Schlitt
218 schema:givenName Hans Jürgen
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53
220 rdf:type schema:Person
221 sg:person.01052221134.13 schema:affiliation grid-institutes:grid.7727.5
222 schema:familyName Hofstädter
223 schema:givenName Ferdinand
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052221134.13
225 rdf:type schema:Person
226 sg:person.01055256602.17 schema:affiliation grid-institutes:grid.7727.5
227 schema:familyName Klinkhammer-Schalke
228 schema:givenName Monika
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055256602.17
230 rdf:type schema:Person
231 sg:person.01114704666.73 schema:affiliation grid-institutes:grid.7727.5
232 schema:familyName Itzel
233 schema:givenName Timo
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114704666.73
235 rdf:type schema:Person
236 sg:person.01171747331.28 schema:affiliation grid-institutes:grid.7727.5
237 schema:familyName Fichtner-Feigl
238 schema:givenName Stefan
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171747331.28
240 rdf:type schema:Person
241 sg:person.01304333475.28 schema:affiliation grid-institutes:grid.7727.5
242 schema:familyName Stroszczynski
243 schema:givenName Christian
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304333475.28
245 rdf:type schema:Person
246 sg:person.013647415541.23 schema:affiliation grid-institutes:grid.7727.5
247 schema:familyName Gerken
248 schema:givenName Michael
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647415541.23
250 rdf:type schema:Person
251 sg:person.0637310151.42 schema:affiliation grid-institutes:grid.7727.5
252 schema:familyName Hartl
253 schema:givenName Janine
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637310151.42
255 rdf:type schema:Person
256 sg:person.0705653251.86 schema:affiliation grid-institutes:grid.7727.5
257 schema:familyName Teufel
258 schema:givenName Andreas
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705653251.86
260 rdf:type schema:Person
261 grid-institutes:grid.7727.5 schema:alternateName Department of Medicine I, University of Regensburg, Regensburg, Germany
262 Department of Radiology, University of Regensburg, Regensburg, Germany
263 Department of Surgery, University of Regensburg, Regensburg, Germany
264 Tumor Center, University of Regensburg, Regensburg, Germany
265 schema:name Department of Medicine I, University of Regensburg, Regensburg, Germany
266 Department of Radiology, University of Regensburg, Regensburg, Germany
267 Department of Surgery, University of Regensburg, Regensburg, Germany
268 Tumor Center, University of Regensburg, Regensburg, Germany
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...